These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 18479914)

  • 1. Allosteric inhibitors of Akt1 and Akt2: a naphthyridinone with efficacy in an A2780 tumor xenograft model.
    Bilodeau MT; Balitza AE; Hoffman JM; Manley PJ; Barnett SF; Defeo-Jones D; Haskell K; Jones RE; Leander K; Robinson RG; Smith AM; Huber HE; Hartman GD
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3178-82. PubMed ID: 18479914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and structure based optimization of novel Akt inhibitors.
    Lippa B; Pan G; Corbett M; Li C; Kauffman GS; Pandit J; Robinson S; Wei L; Kozina E; Marr ES; Borzillo G; Knauth E; Barbacci-Tobin EG; Vincent P; Troutman M; Baker D; Rajamohan F; Kakar S; Clark T; Morris J
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3359-63. PubMed ID: 18456494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines.
    Deady LW; Rodemann T; Zhuang L; Baguley BC; Denny WA
    J Med Chem; 2003 Mar; 46(6):1049-54. PubMed ID: 12620081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allosteric inhibitors of Akt1 and Akt2: discovery of [1,2,4]triazolo[3,4-f][1,6]naphthyridines with potent and balanced activity.
    Li Y; Liang J; Siu T; Hu E; Rossi MA; Barnett SF; Defeo-Jones D; Jones RE; Robinson RG; Leander K; Huber HE; Mittal S; Cosford N; Prasit P
    Bioorg Med Chem Lett; 2009 Feb; 19(3):834-6. PubMed ID: 19097777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Azole-based inhibitors of AKT/PKB for the treatment of cancer.
    Zeng Q; Allen JG; Bourbeau MP; Wang X; Yao G; Tadesse S; Rider JT; Yuan CC; Hong FT; Lee MR; Zhang S; Lofgren JA; Freeman DJ; Yang S; Li C; Tominey E; Huang X; Hoffman D; Yamane HK; Fotsch C; Dominguez C; Hungate R; Zhang X
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1559-64. PubMed ID: 20137943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridin-(5H)ones.
    Deady LW; Rogers ML; Zhuang L; Baguley BC; Denny WA
    Bioorg Med Chem; 2005 Feb; 13(4):1341-55. PubMed ID: 15670942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity.
    Zhu GD; Gong J; Claiborne A; Woods KW; Gandhi VB; Thomas S; Luo Y; Liu X; Shi Y; Guan R; Magnone SR; Klinghofer V; Johnson EF; Bouska J; Shoemaker A; Oleksijew A; Stoll VS; De Jong R; Oltersdorf T; Li Q; Rosenberg SH; Giranda VL
    Bioorg Med Chem Lett; 2006 Jun; 16(12):3150-5. PubMed ID: 16603355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as antitumor agents. Part 2.
    Tsuzuki Y; Tomita K; Shibamori K; Sato Y; Kashimoto S; Chiba K
    J Med Chem; 2004 Apr; 47(8):2097-109. PubMed ID: 15056007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of 2,3,5-trisubstituted pyridine derivatives as potent allosteric Akt1 and Akt2 inhibitors.
    Hartnett JC; Barnett SF; Bilodeau MT; Defeo-Jones D; Hartman GD; Huber HE; Jones RE; Kral AM; Robinson RG; Wu Z
    Bioorg Med Chem Lett; 2008 Mar; 18(6):2194-7. PubMed ID: 18294842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticancer and immunomodulatory activities of novel 1,8-naphthyridine derivatives.
    Kumar V; Madaan A; Sanna VK; Vishnoi M; Joshi N; Singh AT; Jaggi M; Sharma PK; Irchhaiya R; Burman AC
    J Enzyme Inhib Med Chem; 2009 Oct; 24(5):1169-78. PubMed ID: 19555167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances towards the development of ATP-competitive small-molecule inhibitors of the insulin-like growth factor receptor (IGF-IR).
    Hubbard RD; Wilsbacher JL
    ChemMedChem; 2007 Jan; 2(1):41-6. PubMed ID: 17089440
    [No Abstract]   [Full Text] [Related]  

  • 13. Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design.
    Donald A; McHardy T; Rowlands MG; Hunter LJ; Davies TG; Berdini V; Boyle RG; Aherne GW; Garrett MD; Collins I
    J Med Chem; 2007 May; 50(10):2289-92. PubMed ID: 17451235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
    Li Q; Woods KW; Thomas S; Zhu GD; Packard G; Fisher J; Li T; Gong J; Dinges J; Song X; Abrams J; Luo Y; Johnson EF; Shi Y; Liu X; Klinghofer V; Des Jong R; Oltersdorf T; Stoll VS; Jakob CG; Rosenberg SH; Giranda VL
    Bioorg Med Chem Lett; 2006 Apr; 16(7):2000-7. PubMed ID: 16413780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antineoplastic agents 491. Synthetic conversion of aaptamine to isoaaptamine, 9-demethylaaptamine, and 4-methylaaptamine.
    Pettit GR; Hoffmann H; Herald DL; McNulty J; Murphy A; Higgs KC; Hamel E; Lewin NE; Pearce LV; Blumberg PM; Pettit RK; Knight JC
    J Org Chem; 2004 Apr; 69(7):2251-6. PubMed ID: 15049616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.
    Mannion M; Raeppel S; Claridge S; Zhou N; Saavedra O; Isakovic L; Zhan L; Gaudette F; Raeppel F; Déziel R; Beaulieu N; Nguyen H; Chute I; Beaulieu C; Dupont I; Robert MF; Lefebvre S; Dubay M; Rahil J; Wang J; Ste-Croix H; Robert Macleod A; Besterman JM; Vaisburg A
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6552-6. PubMed ID: 19854051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of potent, allosteric dual Akt1 and Akt2 inhibitors with improved physical properties and cell activity.
    Zhao Z; Robinson RG; Barnett SF; Defeo-Jones D; Jones RE; Hartman GD; Huber HE; Duggan ME; Lindsley CW
    Bioorg Med Chem Lett; 2008 Jan; 18(1):49-53. PubMed ID: 18054229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeutics.
    Zeng Q; Bourbeau MP; Wohlhieter GE; Yao G; Monenschein H; Rider JT; Lee MR; Zhang S; Lofgren J; Freeman D; Li C; Tominey E; Huang X; Hoffman D; Yamane H; Tasker AS; Dominguez C; Viswanadhan VN; Hungate R; Zhang X
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1652-6. PubMed ID: 20137932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode.
    Finlay MR; Acton DG; Andrews DM; Barker AJ; Dennis M; Fisher E; Graham MA; Green CP; Heaton DW; Karoutchi G; Loddick SA; Morgentin R; Roberts A; Tucker JA; Weir HM
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4442-6. PubMed ID: 18617397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1,8-Naphthyridine-3-carboxamide derivatives with anticancer and anti-inflammatory activity.
    Kumar V; Jaggi M; Singh AT; Madaan A; Sanna V; Singh P; Sharma PK; Irchhaiya R; Burman AC
    Eur J Med Chem; 2009 Aug; 44(8):3356-62. PubMed ID: 19361894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.